Disease | multiple endocrine neoplasia type 1 |
Comorbidity | C0281361|pancreatic adenocarcinoma |
Sentences | 2 |
PubMedID- 24641937 | Conclusions: the addition of enoxaparin to gffc chemotherapy is feasible, safe and does not appear to affect the efficacy or the toxicity profile of the chemotherapy regimen in patients with advanced pancreatic adenocarcinoma. |
PubMedID- 22969226 | Aim: to evaluate the efficacy and safety of the folfiri regimen in patients with metastatic pancreatic adenocarcinoma (pac) after the failure of gemcitabine and platinum salts. |
Page: 1